Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Mylan Inc    MYL   US6285301072


SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Mylan Inc. : Mylan Launches First Generic Version of Doryx® 150 mg

04/30/2012 | 02:20pm US/Eastern

PITTSBURGH, April 30, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg, following a favorable decision by the U.S. District Court for the District of New Jersey in a patent infringement lawsuit brought by Warner Chilcott. The Court held, after trial, that Mylan's product does not infringe the subject patent. Mylan is shipping product immediately.

Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg is the generic version of Mayne Pharma's Doryx(®) 150 mg product (marketed by Warner Chilcott), and is a tetracycline-class antimicrobial.

Doxycycline Hyclate DR Tablets, 150 mg, had U.S. sales of approximately $264.1 million for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit For more information about generic drugs, please visit

SOURCE Mylan Inc.

React to this article
Latest news on MYLAN INC
4d ago MYLAN : Launches Generic Robaxin® Injection
5d ago MYLAN : World TeamTennis and Mylan Announce Title Sponsorship Extension Through ..
5d ago MYLAN : Patent Application Titled "Medicament Information System and Method" Pub..
5d ago Mylan Launches One of First Available Generic Versions of Celebrex® Capsules
5d ago MYLAN : Launches First Generic Version of Orapred ODT®
5d ago MYLAN : to Present at the J.P. Morgan 33rd Annual Healthcare Conference
12/11 Mylan launches generic version of Celebrex
12/11 MYLAN : Inversion to trigger early payday for Mylan executives
12/11 MYLAN : Launches Generic Robaxin® Injection
12/11 MYLAN : Launches First Generic Version of Orapred ODT®
Dynamic quotes